| Stereochemistry | RACEMIC |
| Molecular Formula | C12H16N2 |
| Molecular Weight | 188.2688 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC(N)CC1=CNC2=CC=CC=C12
InChI
InChIKey=ZXUMUPVQYAFTLF-UHFFFAOYSA-N
InChI=1S/C12H16N2/c1-2-10(13)7-9-8-14-12-6-4-3-5-11(9)12/h3-6,8,10,14H,2,7,13H2,1H3
| Molecular Formula | C12H16N2 |
| Molecular Weight | 188.2688 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
ETRYPTAMINE (MONASE®), similar to the hallucinogenic tryptamines, is an inhibitor of monoamine oxidase, introduced for use as an antidepressant. It was withdrawn from the market due to problems with agranulocytosis and other side effects. However, it's activity is still under scientific investigation.
CNS Activity
Originator
Approval Year
Doses
AEs
Sourcing
PubMed
Patents
|
|
SALT/SOLVATE -> PARENT |
|
||
|
|
ENANTIOMER -> RACEMATE |
|
||
|
|
ENANTIOMER -> RACEMATE |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
Showing 1 to 4 of 4 entries
